

Craig C Earle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9733492/publications.pdf>

Version: 2024-02-01

283
papers

17,984
citations

13827

67
h-index

15218

126
g-index

286
all docs

286
docs citations

286
times ranked

16080
citing authors

#	ARTICLE	IF	CITATIONS
1	Early palliative care and quality of dying and death in patients with advanced cancer. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e74-e77.	0.8	5
2	Breast Density and Risk of Interval Cancers: The Effect of Annual Versus Biennial Screening Mammography Policies in Canada. <i>Canadian Association of Radiologists Journal</i> , 2022, 73, 90-100.	1.1	18
3	Caregiver bereavement outcomes in advanced cancer: associations with quality of death and patient age. <i>Supportive Care in Cancer</i> , 2022, 30, 1343-1353.	1.0	11
4	Reply to K. Kajiwara et al. concerning "Caregiver bereavement outcomes in advanced cancer: associations with quality of death and patient age" <i>Supportive Care in Cancer</i> , 2022, 30, 2903-2904.	1.0	0
5	The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes. <i>Annals of Hematology</i> , 2022, 101, 1023-1030.	0.8	3
6	Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer. <i>JAMA Network Open</i> , 2022, 5, e2145460.	2.8	6
7	Assessing the Impact of the COVID-19 Pandemic on Emergency Department Use for Patients Undergoing Cancer-Directed Surgeries. <i>Current Oncology</i> , 2022, 29, 1877-1889.	0.9	4
8	Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	4
9	Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada. <i>International Journal of Cancer</i> , 2021, 148, 1910-1918.	2.3	4
10	Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces. <i>MDM Policy and Practice</i> , 2021, 6, 238146832110210.	0.5	10
11	Salvage surgery for locally recurrent anal cancer after intensity modulated radiation therapy with concurrent chemotherapy. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100287.	0.7	2
12	The cost of chemotherapy administration: a systematic review and meta-analysis. <i>European Journal of Health Economics</i> , 2021, 22, 605-620.	1.4	2
13	Comparison of Multiparametric Magnetic Resonance Imaging "Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 534.	3.4	99
14	Development and validation of a prediction model of poor performance status and severe symptoms over time in cancer patients (PROVIEW+). <i>Palliative Medicine</i> , 2021, 35, 1713-1723.	1.3	7
15	High-Intensity vs Low-Intensity Knowledge Translation Interventions for Surgeons and Their Association With Process and Outcome Measures Among Patients Undergoing Rectal Cancer Surgery. <i>JAMA Network Open</i> , 2021, 4, e2117536.	2.8	4
16	Impact of Palliative Care Involvement on End-of-Life Care Patterns Among Adolescents and Young Adults With Cancer: A Population-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2506-2515.	0.8	28
17	Transforming Canada's role in global cancer control. <i>Lancet Oncology</i> , The, 2021, 22, e400-e409.	5.1	6
18	Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada. <i>Journal of Thoracic Disease</i> , 2021, 13, 5419-5429.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia. <i>JCO Oncology Practice</i> , 2021, 17, e517-e525.	1.4	4
20	Canadian Cancer Centre Response to COVID-19 Pandemic: A National and Provincial Response. <i>Current Oncology</i> , 2021, 28, 233-251.	0.9	14
21	The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. <i>Breast</i> , 2021, 60, 295-301.	0.9	2
22	The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer. <i>JAMA Network Open</i> , 2021, 4, e2133388.	2.8	3
23	Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise. <i>Current Oncology</i> , 2021, 28, 4645-4654.	0.9	10
24	The Impact of Oral Hypoglycemics and Statins on Outcomes in Myelodysplastic Syndromes. <i>Blood</i> , 2021, 138, 3064-3064.	0.6	1
25	Building capacity for palliative care delivery in primary care settings. <i>Canadian Family Physician</i> , 2021, 67, 270-278.	0.1	10
26	Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 379-385.	0.5	1
27	Are We Choosing Surveillance Imaging in Gastric and Pancreatic Cancers Wisely? A Population-Based Study. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 189-195.	0.6	2
28	Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 217-227.	1.1	16
29	Variation in receipt of therapy and survival with provider volume for medical oncology in non-curative esophago-gastric cancer: a population-based analysis. <i>Gastric Cancer</i> , 2020, 23, 300-309.	2.7	5
30	Days spent at home in the last 6 months of life: a quality indicator of end of life care in patients with hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2020, 61, 146-155.	0.6	15
31	Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis. <i>Cancer Medicine</i> , 2020, 9, 160-169.	1.3	55
32	Directly Mailing gFOBT Kits to Previous Responders Being Recalled for Colorectal Cancer Screening Increases Participation. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 197-203.	0.1	0
33	Value assessment of oncology drugs using a weighted criterion-based approach. <i>Cancer</i> , 2020, 126, 1530-1540.	2.0	13
34	Economic impacts of care by high-volume providers for non-curative esophagogastric cancer: a population-based analysis. <i>Gastric Cancer</i> , 2020, 23, 373-381.	2.7	3
35	Material deprivation and access to cancer care in a universal health care system. <i>Cancer</i> , 2020, 126, 4545-4552.	2.0	12
36	The impact of routine Edmonton Symptom Assessment System (ESAS) use on overall survival in cancer patients: Results of a population-based retrospective matched cohort analysis. <i>Cancer Medicine</i> , 2020, 9, 7107-7115.	1.3	52

#	ARTICLE	IF	CITATIONS
37	Symptom Burden of Nonresected Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2020, 49, 1083-1089.	0.5	11
38	A method to audit and score implementation of knowledge translation (KT) interventions in large health regions – an observational pilot study using rectal cancer surgery in Ontario. <i>BMC Health Services Research</i> , 2020, 20, 506.	0.9	3
39	Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study. <i>CMAJ Open</i> , 2020, 8, E191-E198.	1.1	15
40	The association between endocrine therapy use and dementia among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1132-1137.	0.5	7
41	Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the “real-world”™. <i>Leukemia and Lymphoma</i> , 2020, 61, 1445-1454.	0.6	5
42	Operationalizing Outpatient Palliative Care Referral Criteria in Lung Cancer Patients: A Population-Based Cohort Study Using Health Administrative Data. <i>Journal of Palliative Medicine</i> , 2020, 23, 670-677.	0.6	5
43	Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 155-165.	1.1	14
44	Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada. <i>Leukemia and Lymphoma</i> , 2020, 61, 1908-1919.	0.6	9
45	Assessing the Impact of Early Identification of Patients Appropriate for Palliative Care on Resource Use and Costs in the Final Month of Life. <i>JCO Oncology Practice</i> , 2020, 16, e688-e702.	1.4	3
46	Development and Validation of a Prognostic Survival Model With Patient-Reported Outcomes for Patients With Cancer. <i>JAMA Network Open</i> , 2020, 3, e201768.	2.8	16
47	Integration of patient-reported outcomes (PROs) for personalized symptom management in “real-world” oncology practices: a population-based cohort comparison study of impact on healthcare utilization. <i>Supportive Care in Cancer</i> , 2020, 28, 4933-4942.	1.0	28
48	Does early palliative identification improve the use of palliative care services?. <i>PLoS ONE</i> , 2020, 15, e0226597.	1.1	18
49	Benefits of High-Volume Medical Oncology Care for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 297-303.	2.3	8
50	Impact of Geography on Care Delivery and Survival for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1642-1650.	2.3	7
51	High-Cost Patients and Preventable Spending: A Population-Based Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 23-31.	2.3	10
52	Understanding Long-Term Cancer Survivors’™ Preferences for Ongoing Medical Care. <i>Journal of General Internal Medicine</i> , 2019, 34, 2091-2097.	1.3	23
53	Prevalence of Inappropriateness of Parenteral Vitamin B ₁₂ Administration in Ontario, Canada. <i>JAMA Internal Medicine</i> , 2019, 179, 1434.	2.6	10
54	Influenza Vaccine Effectiveness Among Patients With Cancer: A Population-Based Study Using Health Administrative and Laboratory Testing Data From Ontario, Canada. <i>Journal of Clinical Oncology</i> , 2019, 37, 2795-2804.	0.8	41

#	ARTICLE	IF	CITATIONS
55	Population-Level Symptom Assessment Following Pancreaticoduodenectomy for Adenocarcinoma. <i>JAMA Surgery</i> , 2019, 154, e193348.	2.2	30
56	Symptom trajectories and predictors of severe symptoms in pancreatic adenocarcinoma at the end-of-life: a population based analysis of 2,538 patients. <i>Hpb</i> , 2019, 21, 1744-1752.	0.1	5
57	Economic Analysis of Adjuvant Chemoradiotherapy Compared with Chemotherapy in Resected Pancreas Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 4193-4203.	0.7	3
58	Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis. <i>Cmaj</i> , 2019, 191, E574-E580.	0.9	21
59	Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs. <i>Heart</i> , 2019, 105, 1649-1655.	1.2	7
60	Factors Associated With Opioid Use in Long-term Cancer Survivors. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 100-107.e2.	0.6	18
61	Access to Palliative Care for Cancer Patients Living in a Northern and Rural Environment in Ontario, Canada: The Effects of Geographic Region and Rurality on End-of-Life Care in a Population-Based Decedent Cancer Cohort. <i>Clinical Medicine Insights: Oncology</i> , 2019, 13, 117955491982950.	0.6	25
62	How Do Blood Cancer Doctors Discuss Prognosis? Findings from a National Survey of Hematologic Oncologists. <i>Journal of Palliative Medicine</i> , 2019, 22, 677-684.	0.6	20
63	Integrating early palliative care into routine practice for patients with cancer: A mixed methods evaluation of the INTEGRATE Project. <i>Psycho-Oncology</i> , 2019, 28, 1261-1268.	1.0	24
64	Days at Home in the Last 6 Months of Life: A Patient-Determined Quality Indicator for Cancer Care. <i>Journal of Oncology Practice</i> , 2019, 15, e308-e315.	2.5	20
65	Demographic characteristics and cost of treatment among oncology patients in a publicly funded system, the Ontario Trillium Drug Program: a retrospective cohort study. <i>CMAJ Open</i> , 2019, 7, E516-E523.	1.1	2
66	Can Administrative Data Improve the Performance of Cancer Clinical Trial Economic Analyses?. <i>Journal of Oncology Practice</i> , 2019, 15, e807-e824.	2.5	10
67	216 The Impact of Routine ESAS Use on Emergency Department Visits and Hospitalizations: A Population-Based Retrospective Matched Cohort Study. <i>Radiotherapy and Oncology</i> , 2019, 139, S90-S91.	0.3	0
68	Pilot study of the ability to probabilistically link clinical trial patients to administrative data and determine long-term outcomes. <i>Clinical Trials</i> , 2019, 16, 14-17.	0.7	6
69	Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions. <i>Cancer Epidemiology</i> , 2019, 58, 184-192.	0.8	20
70	Methods to improve the estimation of time-to-event outcomes when data is de-identified. <i>Statistics in Medicine</i> , 2019, 38, 625-635.	0.8	0
71	Factors Associated with Health Care Resource Utilization in Myeloproliferative Neoplasms: A Population-Based Cost Study. <i>Blood</i> , 2019, 134, 4169-4169.	0.6	0
72	Chinese and South Asian ethnicity, immigration status, and clinical cancer outcomes in the Ontario Cancer System. <i>Cancer</i> , 2018, 124, 1473-1482.	2.0	9

#	ARTICLE	IF	CITATIONS
73	A Population-Based Study of Complications After Colorectal Surgery in Patients Who Have Received Bevacizumab. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 306-313.	0.7	12
74	Simulating results from trials of sigmoidoscopy screening using the OncoSim microsimulation model. <i>Journal of Cancer Policy</i> , 2018, 15, 52-58.	0.6	9
75	Investigation of the international comparability of population-based routine hospital data set derived comorbidity scores for patients with lung cancer. <i>Thorax</i> , 2018, 73, 339-349.	2.7	12
76	Comparison of Opioid Prescribing Among Cancer and Noncancer Patients Aged 18-64: Analysis Using Administrative Data. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 72-79.	0.6	9
77	Are We Choosing Wisely in Lymphoma? Excessive Use of Surveillance CT Imaging in Patients With Diffuse Large B-cell Lymphoma (DLBCL) in Long-term Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e27-e34.	0.2	10
78	Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer, 1995 to 2013. <i>Cancer</i> , 2018, 124, 1269-1278.	2.0	20
79	Predictors of Specialized Pediatric Palliative Care Involvement and Impact on Patterns of End-of-Life Care in Children With Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 801-807.	0.8	50
80	Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment. <i>Journal of Clinical Oncology</i> , 2018, 36, 1121-1127.	0.8	70
81	Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay. <i>Journal of Clinical Oncology</i> , 2018, 36, 238-243.	0.8	26
82	Examination of Health System Resources and Costs Associated With Transitioning Cancer Survivors to Primary Care: A Propensity-Score-Matched Cohort Study. <i>Journal of Oncology Practice</i> , 2018, 14, e653-e664.	2.5	10
83	Improving access to cancer care together with Indigenous peoples. <i>The Lancet Global Health</i> , 2018, 6, S3-S4.	2.9	1
84	Synchronous anal canal carcinoma in a heterosexual couple. <i>BMC Cancer</i> , 2018, 18, 884.	1.1	0
85	Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 235-242.	1.1	10
86	Resource utilization and disaggregated cost analysis for initial treatment of melanoma. <i>Journal of Cancer Policy</i> , 2018, 16, 63-69.	0.6	4
87	Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 449-459.	1.1	20
88	High Healthcare Utilization and Costs in Patients with Higher-Risk MDS/Low Blast Count AML Treated with Azacitidine in Ontario, Canada. <i>Blood</i> , 2018, 132, 834-834.	0.6	2
89	The Impact of Increasing Hospital Volume on 90-Day Postoperative Outcomes Following Pancreaticoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 506-515.	0.9	40
90	Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, Canada. <i>International Journal of Cancer</i> , 2017, 140, 2162-2167.	2.3	4

#	ARTICLE	IF	CITATIONS
91	The Validity of Using Health Administrative Data To Identify the Involvement of Specialized Pediatric Palliative Care Teams in Children with Cancer in Ontario, Canada. <i>Journal of Palliative Medicine</i> , 2017, 20, 1210-1216.	0.6	5
92	Why are patients with blood cancers more likely to die without hospice?. <i>Cancer</i> , 2017, 123, 3377-3384.	2.0	61
93	Physician agency and patient survival. <i>Journal of Economic Behavior and Organization</i> , 2017, 134, 27-47.	1.0	16
94	Opioid Prescribing Among Cancer and Non-cancer Patients: Time Trend Analysis in the Elderly Using Administrative Data. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 484-492.e1.	0.6	23
95	Projected effect of fecal immunochemical test threshold for colorectal cancer screening on outcomes and costs for Canada using the OncoSim microsimulation model. <i>Journal of Cancer Policy</i> , 2017, 13, 38-46.	0.6	9
96	Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with personal-level data in a Canadian setting. <i>Cancer Medicine</i> , 2017, 6, 2017-2033.	1.3	18
97	Response. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	0
98	The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw226.	3.0	22
99	Has Province-Wide Symptom Screening Changed Opioid Prescribing Rates in Older Patients With Cancer?. <i>Journal of Oncology Practice</i> , 2017, 13, e927-e934.	2.5	3
100	Predictors of and Trends in High-Intensity End-of-Life Care Among Children With Cancer: A Population-Based Study Using Health Services Data. <i>Journal of Clinical Oncology</i> , 2017, 35, 236-242.	0.8	57
101	Impact of Immigration Status on Cancer Outcomes in Ontario, Canada. <i>Journal of Oncology Practice</i> , 2017, 13, e602-e612.	2.5	23
102	Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting. <i>PLoS ONE</i> , 2017, 12, e0185198.	1.1	22
103	Effects of socioeconomic status on esophageal adenocarcinoma stage at diagnosis, receipt of treatment, and survival: A population-based cohort study. <i>PLoS ONE</i> , 2017, 12, e0186350.	1.1	14
104	Characteristics and Correlates of Increasing Use of Surgery in Taiwanese Cancer Patients' Last Month of Life, 2001-2010. <i>Annals of Surgery</i> , 2016, 264, 283-290.	2.1	5
105	Effect of socioeconomic status on hepatocellular carcinoma incidence and stage at diagnosis, a population-based cohort study. <i>Liver International</i> , 2016, 36, 902-910.	1.9	21
106	Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study. <i>CMAJ Open</i> , 2016, 4, E66-E72.	1.1	10
107	Relationship Between Quality of Comorbid Condition Care and Costs for Cancer Survivors. <i>Journal of Oncology Practice</i> , 2016, 12, e734-e745.	2.5	4
108	RF2-B Predictors of and Trends in High-Intensity End-of-Life Care Among Children with Cancer: A Population-Based Study Using Health Services Data. <i>Journal of Pain and Symptom Management</i> , 2016, 52, e29.	0.6	0

#	ARTICLE	IF	CITATIONS
109	The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection. <i>Hpb</i> , 2016, 18, 339-347.	0.1	8
110	Beyond the dollar: Influence of sociodemographic marginalization on surgical resection, adjuvant therapy, and survival in patients with pancreatic cancer. <i>Cancer</i> , 2016, 122, 3175-3182.	2.0	39
111	Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 535-544.	1.1	23
112	Barriers to Quality End-of-Life Care for Patients With Blood Cancers. <i>Journal of Clinical Oncology</i> , 2016, 34, 3126-3132.	0.8	108
113	Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 333-340.	1.1	8
114	Phase-specific healthcare costs of cervical cancer: estimates from a population-based study. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 615.e1-615.e11.	0.7	16
115	Family Perspectives on Aggressive Cancer Care Near the End of Life. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 284.	3.8	341
116	Hospice Use Among Patients With Lymphoma: Impact of Disease Aggressiveness and Curability. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv280.	3.0	47
117	Incidence of Diabetes in Colorectal Cancer Survivors. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv402.	3.0	51
118	Timeliness of End-of-Life Discussions for Blood Cancers. <i>JAMA Internal Medicine</i> , 2016, 176, 263.	2.6	45
119	The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv301.	3.0	62
120	Are We Choosing Wisely in Lymphoma? Excessive Use of Surveillance CT Imaging in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Long-Term Remission. <i>Blood</i> , 2016, 128, 692-692.	0.6	1
121	Impact of aggressive management and palliative care on cancer costs in the final month of life. <i>Cancer</i> , 2015, 121, 3307-3315.	2.0	133
122	Increasing participation in colorectal cancer screening: Results from a cluster randomized trial of directly mailed g<scp>FOBT</scp> kits to previous nonresponders. <i>International Journal of Cancer</i> , 2015, 136, E697-703.	2.3	22
123	Population-Based Assessment of Emergency Room Visits and Hospitalizations Among Women Receiving Adjuvant Chemotherapy for Early Breast Cancer. <i>Journal of Oncology Practice</i> , 2015, 11, 126-132.	2.5	56
124	Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?. <i>Cancer</i> , 2015, 121, 2562-2569.	2.0	71
125	Choosing Wisely Canada Cancer List: Ten Low-Value or Harmful Practices That Should Be Avoided In Cancer Care. <i>Journal of Oncology Practice</i> , 2015, 11, e296-e303.	2.5	52
126	Comorbid condition care quality in cancer survivors: role of primary care and specialty providers and care coordination. <i>Journal of Cancer Survivorship</i> , 2015, 9, 641-649.	1.5	47

#	ARTICLE	IF	CITATIONS
127	The expanding role of primary care in cancer control. <i>Lancet Oncology</i> , 2015, 16, 1231-1272.	5.1	399
128	Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 137-145.	1.1	6
129	Measuring Quality of End-of-Life Care for Blood Cancers: A National Survey of Hematologic Oncologists. <i>Blood</i> , 2015, 126, 3290-3290.	0.6	3
130	Improved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0138907.	1.1	22
131	The Association of Dyslipidemia with the Development of Chronic Lymphocytic Leukemia: A Population-Based Study. <i>Blood</i> , 2015, 126, 5268-5268.	0.6	0
132	Secure Surveillance of Antimicrobial Resistant Organism Colonization or Infection in Ontario Long Term Care Homes. <i>PLoS ONE</i> , 2014, 9, e93285.	1.1	10
133	End-of-Life Care for Older Patients With Ovarian Cancer Is Intensive Despite High Rates of Hospice Use. <i>Journal of Clinical Oncology</i> , 2014, 32, 3534-3539.	0.8	63
134	Processes of Care in the Multidisciplinary Treatment of Gastric Cancer. <i>JAMA Surgery</i> , 2014, 149, 18.	2.2	36
135	Utilization and costs of home care for patients with colorectal cancer: a population-based study. <i>CMAJ Open</i> , 2014, 2, E11-E17.	1.1	22
136	Optimal Management of Gastric Cancer. <i>Annals of Surgery</i> , 2014, 259, 102-108.	2.1	48
137	It's who you know: patient-sharing, quality, and costs of cancer survivorship care. <i>Journal of Cancer Survivorship</i> , 2014, 8, 156-166.	1.5	35
138	Is More Intensive Surveillance Really a Good Idea for High-Risk Patients With Colorectal Cancer?. <i>Journal of Clinical Oncology</i> , 2014, 32, 1518-1518.	0.8	2
139	Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 134, 473-477.	0.6	18
140	Repeated Assessments of Symptom Severity Improve Predictions for Risk of Death Among Patients With Cancer. <i>Journal of Pain and Symptom Management</i> , 2014, 48, 1041-1049.	0.6	16
141	Home care utilization and costs in stage IV lung cancer: a Canadian public payer experience. <i>Lung Cancer Management</i> , 2014, 3, 439-442.	1.5	0
142	End-of-life home care utilization and costs in patients with advanced colorectal cancer. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 92-98.	0.1	9
143	Physician preferences and attitudes regarding different models of cancer survivorship care: a comparison of primary care providers and oncologists. <i>Journal of Cancer Survivorship</i> , 2013, 7, 343-354.	1.5	105
144	Income and outcome in myelodysplastic syndrome: The prognostic impact of SES in a single-payer system. <i>Leukemia Research</i> , 2013, 37, 1495-1501.	0.4	3

#	ARTICLE	IF	CITATIONS
145	Defining Surgical Quality in Gastric Cancer: A RAND/UCLA Appropriateness Study. <i>Journal of the American College of Surgeons</i> , 2013, 217, 347-357e1.	0.2	42
146	The Association of the Palliative Performance Scale and Hazard of Death in an Ambulatory Cancer Population. <i>Journal of Palliative Medicine</i> , 2013, 16, 156-162.	0.6	26
147	Barriers to Breast and Colorectal Cancer Survivorship Care: Perceptions of Primary Care Physicians and Medical Oncologists in the United States. <i>Journal of Clinical Oncology</i> , 2013, 31, 2322-2336.	0.8	81
148	Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America. <i>Gastric Cancer</i> , 2013, 16, 28-40.	2.7	48
149	Modeling the Longitudinal Transitions of Performance Status in Cancer Outpatients: Time to Discuss Palliative Care. <i>Journal of Pain and Symptom Management</i> , 2013, 45, 726-734.	0.6	25
150	Health care costs associated with hepatocellular carcinoma: A population-based study. <i>Hepatology</i> , 2013, 58, 1375-1384.	3.6	64
151	A RAND/UCLA Appropriateness Study of the Management of Familial Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 533-541.	0.7	12
152	A secure distributed logistic regression protocol for the detection of rare adverse drug events. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2013, 20, 453-461.	2.2	52
153	Quality of Care for Comorbid Conditions During the Transition to Survivorship: Differences Between Cancer Survivors and Noncancer Controls. <i>Journal of Clinical Oncology</i> , 2013, 31, 1140-1148.	0.8	74
154	Frequency of Non-Cancer-Related Pain in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 2837-2837.	0.8	8
155	Introduction to the ASCO Quality Care Symposium. <i>Journal of Oncology Practice</i> , 2013, 9, 113-113.	2.5	0
156	CANADIAN CANCER RISK MANAGEMENT MODEL: EVALUATION OF CANCER CONTROL. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 131-139.	0.2	29
157	Surveillance after resection for colorectal cancer. <i>Cancer</i> , 2013, 119, 1235-1242.	2.0	24
158	Physicians' Beliefs About Breast Cancer Surveillance Testing are Consistent With Test Overuse. <i>Medical Care</i> , 2013, 51, 315-323.	1.1	33
159	Physician roles in the cancer-related follow-up care of cancer survivors. <i>Family Medicine</i> , 2013, 45, 463-74.	0.3	88
160	Closing the personalized medicine information gap: HER2 test documentation practice. <i>American Journal of Managed Care</i> , 2013, 19, 838-44.	0.8	5
161	Reply to E. Warner. <i>Journal of Clinical Oncology</i> , 2012, 30, 1893-1894.	0.8	0
162	Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors. <i>Journal of Clinical Oncology</i> , 2012, 30, 2963-2968.	0.8	257

#	ARTICLE	IF	CITATIONS
163	Reply to M.A. Hoffman et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 2802-2802.	0.8	0
164	Role of Comparative Effectiveness Research in Cancer Funding Decisions in Ontario, Canada. <i>Journal of Clinical Oncology</i> , 2012, 30, 4262-4266.	0.8	9
165	Cancer Survivorship Care: Don't Let the Perfect Be the Enemy of the Good. <i>Journal of Clinical Oncology</i> , 2012, 30, 3764-3768.	0.8	76
166	<i>Journal of Clinical Oncology</i> Update on Progress in Cancer Survivorship Care and Research. <i>Journal of Clinical Oncology</i> , 2012, 30, 3655-3656.	0.8	31
167	Associations Between End-of-Life Discussion Characteristics and Care Received Near Death: A Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 4387-4395.	0.8	457
168	End-of-Life Care Discussions Among Patients With Advanced Cancer. <i>Annals of Internal Medicine</i> , 2012, 156, 204.	2.0	341
169	Association of Hospital Spending Intensity With Mortality and Readmission Rates in Ontario Hospitals. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1037.	3.8	125
170	The evaluation of cancer control interventions in lung cancer using the Canadian Cancer Risk Management Model. <i>Lung Cancer Management</i> , 2012, 1, 25-33.	1.5	10
171	A Protocol for the Secure Linking of Registries for HPV Surveillance. <i>PLoS ONE</i> , 2012, 7, e39915.	1.1	17
172	Stability of Azacitidine in Sterile Water for Injection. <i>Canadian Journal of Hospital Pharmacy</i> , 2012, 65, 352-9.	0.1	15
173	Referrals for suspected hematologic malignancy: A survey of primary care physicians. <i>American Journal of Hematology</i> , 2012, 87, 634-636.	2.0	15
174	Disparities in hospice care among older women dying with ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 125, 14-18.	0.6	67
175	Adjuvant therapy for elderly patients with resected gastric adenocarcinoma. <i>Cancer</i> , 2012, 118, 248-257.	2.0	22
176	Influence of Socioeconomic Status on Survival of Hepatocellular Carcinoma in the Ontario Population; A Population-Based Study, 1990â€“2009. <i>PLoS ONE</i> , 2012, 7, e40917.	1.1	36
177	Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. <i>Value in Health</i> , 2011, 14, 41-52.	0.1	99
178	Geographic Variation in Physicians' Responses to a Reimbursement Change. <i>New England Journal of Medicine</i> , 2011, 365, 2049-2052.	13.9	27
179	Cancer Stage Comparison Between Dual Medicare-Medicaid Eligibles Using Medicaid as a Supplemental Health Insurance Program and Low-Income Nonduals. <i>Journal of Public Health Management and Practice</i> , 2011, 17, 479-491.	0.7	8
180	Quality of Care for Older Patients With Cancer in the Veterans Health Administration Versus the Private Sector. <i>Annals of Internal Medicine</i> , 2011, 154, 727.	2.0	84

#	ARTICLE	IF	CITATIONS
181	Differences Between Primary Care Physicians'™ and Oncologists'™ Knowledge, Attitudes and Practices Regarding the Care of Cancer Survivors. <i>Journal of General Internal Medicine</i> , 2011, 26, 1403-1410.	1.3	250
182	Preventive care in prostate cancer patients: following diagnosis and for five-year survivors. <i>Journal of Cancer Survivorship</i> , 2011, 5, 283-291.	1.5	53
183	Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia. <i>Cancer</i> , 2011, 117, 1470-1477.	2.0	25
184	Association of area sociodemographic characteristics and capacity for treatment with disparities in colorectal cancer care and mortality. <i>Cancer</i> , 2011, 117, 4267-4276.	2.0	51
185	Hospice Care and Survival among Elderly Patients with Lung Cancer. <i>Journal of Palliative Medicine</i> , 2011, 14, 929-939.	0.6	98
186	Trajectory of Performance Status and Symptom Scores for Patients With Cancer During the Last Six Months of Life. <i>Journal of Clinical Oncology</i> , 2011, 29, 1151-1158.	0.8	352
187	Advancing Performance Measurement in Oncology: Quality Oncology Practice Initiative Participation and Quality Outcomes. <i>Journal of Oncology Practice</i> , 2011, 7, 31s-35s.	2.5	85
188	Association of Diagnostic Radiation Exposure and Second Abdominal-Pelvic Malignancies After Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2883-2888.	0.8	57
189	Trends in the Aggressiveness of End-of-Life Cancer Care in the Universal Health Care System of Ontario, Canada. <i>Journal of Clinical Oncology</i> , 2011, 29, 1587-1591.	0.8	354
190	A Framework for Cancer Survivorship Research and Translation to Policy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2099-2104.	1.1	17
191	A secure protocol for protecting the identity of providers when disclosing data for disease surveillance. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2011, 18, 212-217.	2.2	40
192	Completion of Adjuvant Chemotherapy and Use of Health Services for Older Women With Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3921-3926.	0.8	58
193	The Anemia Workup in Current Clinical Practice: Results From a Survey of Primary Care Physicians. <i>Blood</i> , 2011, 118, 2084-2084.	0.6	0
194	Population-Based Health Care Cost Estimates Related to Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2011, 118, 2068-2068.	0.6	0
195	Outcomes for lymphoid malignancies in the Nurses' Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) Program. <i>Hematological Oncology</i> , 2010, 28, 133-136.	0.8	5
196	Phase II study of pemetrexed in patients with advanced neuroendocrine tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 961-968.	1.1	8
197	End-of-life care for older cancer patients in the Veterans Health Administration versus the private sector. <i>Cancer</i> , 2010, 116, 3732-3739.	2.0	73
198	Association of local capacity for endoscopy with individual use of colorectal cancer screening and stage at diagnosis. <i>Cancer</i> , 2010, 116, 2922-2931.	2.0	20

#	ARTICLE	IF	CITATIONS
199	Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the medicare population. <i>Cancer</i> , 2010, 116, 4840-4848.	2.0	59
200	How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer?. <i>Cancer</i> , 2010, 116, 5391-5399.	2.0	50
201	Symptom burden and performance status in a population-based cohort of ambulatory cancer patients. <i>Cancer</i> , 2010, 116, 5767-5776.	2.0	181
202	Employment Among Survivors of Lung Cancer and Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1700-1705.	0.8	76
203	The Interface Between Primary and Oncology Specialty Care: Treatment Through Survivorship. <i>Journal of the National Cancer Institute Monographs</i> , 2010, 2010, 25-30.	0.9	190
204	When is Cancer Care Cost-Effective? A Systematic Overview of Cost-Utility Analyses in Oncology. <i>Journal of the National Cancer Institute</i> , 2010, 102, 82-88.	3.0	163
205	Primary Care Referrals for Suspected Hematologic Malignancies: Incidence, Factors Affecting Choice of Specialist, and Flow of Referral Information.. <i>Blood</i> , 2010, 116, 3830-3830.	0.6	0
206	Cancer Quality Alliance Proceedings: Caring Beyond Cancer. <i>Journal of Oncology Practice</i> , 2009, 5, 265-266.	2.5	0
207	Behavioral Health Services for Women Who Have Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 706-712.	0.8	28
208	Comparisons of Patient and Physician Expectations for Cancer Survivorship Care. <i>Journal of Clinical Oncology</i> , 2009, 27, 2489-2495.	0.8	256
209	Impact of Patient Age and Comorbidity on Surgeon Versus Oncologist Preferences for Adjuvant Chemotherapy for Stage III Colon Cancer. <i>Journal of the American College of Surgeons</i> , 2009, 208, 202-209.	0.2	50
210	Factors related to second cancer screening practice in disease-free cervical cancer survivors. <i>Cancer Causes and Control</i> , 2009, 20, 1697-1703.	0.8	14
211	Comparing Care for Breast Cancer Survivors to Non-Cancer Controls: A Five-Year Longitudinal Study. <i>Journal of General Internal Medicine</i> , 2009, 24, 469-474.	1.3	132
212	Racial and Ethnic Differences in End-of-Life Care in Fee-for-Service Medicare Beneficiaries with Advanced Cancer. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 153-158.	1.3	171
213	Costs of First-Line Doublet Chemotherapy and Lifetime Medical Care in Advanced Non-small-Cell Lung Cancer in the United States. <i>Value in Health</i> , 2009, 12, 481-488.	0.1	20
214	Racial Differences in Cancer Specialist Consultation, Treatment, and Outcomes for Locoregional Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2009, 16, 2968-2977.	0.7	112
215	Lifetime and Treatment-Phase Costs Associated With Colorectal Cancer: Evidence from SEER-Medicare Data. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 198-204.	2.4	84
216	Diagnostic delay and complications for older adults with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2009, 50, 392-400.	0.6	59

#	ARTICLE	IF	CITATIONS
217	Etiology of Delays in the Initiation of Adjuvant Chemotherapy and Their Impact on Outcomes for Stage II and III Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 1054-1064.	0.7	95
218	What is the most cost-effective strategy to screen for second primary colorectal cancers in male cancer survivors in Korea?. <i>World Journal of Gastroenterology</i> , 2009, 15, 3153.	1.4	7
219	Diagnostic Delays and Survival for Medicare Patients with Chronic Myeloid Leukemia in the Pre-Imatinib Era.. <i>Blood</i> , 2009, 114, 1369-1369.	0.6	0
220	Phase-II Study of Gemcitabine and Cisplatin in Patients with Metastatic Biliary and Gallbladder Cancer. <i>Digestive Diseases and Sciences</i> , 2008, 53, 564-570.	1.1	56
221	Trends in Follow-up and Preventive Care for Colorectal Cancer Survivors. <i>Journal of General Internal Medicine</i> , 2008, 23, 254-259.	1.3	129
222	Racial Segregation and Disparities in Cancer Stage for Seniors. <i>Journal of General Internal Medicine</i> , 2008, 23, 699-705.	1.3	83
223	Toward population-based indicators of quality end-of-life care. <i>Cancer</i> , 2008, 112, 2301-2308.	2.0	97
224	Racial segregation and disparities in breast cancer care and mortality. <i>Cancer</i> , 2008, 113, 2166-2172.	2.0	345
225	Ten-Year Survival and Cost Following Breast Cancer Recurrence: Estimates from SEER-Medicare Data. <i>Value in Health</i> , 2008, 11, 213-220.	0.1	83
226	Racial Composition of Hospitals: Effects on Surgery for Early-Stage Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4347-4352.	0.8	50
227	Comparison of Prospective and Retrospective Indicators of the Quality of End-of-Life Cancer Care. <i>Journal of Clinical Oncology</i> , 2008, 26, 5671-5678.	0.8	74
228	Aggressiveness of Cancer Care Near the End of Life: Is It a Quality-of-Care Issue?. <i>Journal of Clinical Oncology</i> , 2008, 26, 3860-3866.	0.8	801
229	Delays in referral and diagnosis for chronic hematologic malignancies: A literature review. <i>Leukemia and Lymphoma</i> , 2008, 49, 1352-1359.	0.6	22
230	Diagnostic Patterns of Care and Outcomes for Patients with Chronic Lymphocytic Leukemia in the Surveillance, Epidemiology, and End-Results (SEER)-Medicare Database. <i>Blood</i> , 2008, 112, 2399-2399.	0.6	0
231	Cancer Survivorship Research and Guidelines: Maybe the Cart Should Be Beside the Horse. <i>Journal of Clinical Oncology</i> , 2007, 25, 3800-3801.	0.8	31
232	Referral Patterns, Treatment Choices, and Outcomes in Locoregional Esophageal Cancer: A Population-Based Analysis of Elderly Patients. <i>Journal of Clinical Oncology</i> , 2007, 25, 2389-2396.	0.8	92
233	Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 661-670.	1.1	16
234	Long term care planning for cancer survivors: a health services research agenda. <i>Journal of Cancer Survivorship</i> , 2007, 1, 64-74.	1.5	56

#	ARTICLE	IF	CITATIONS
235	Mental health service utilization among long-term cancer survivors. <i>Journal of Cancer Survivorship</i> , 2007, 1, 156-160.	1.5	31
236	Lower Use of Hospice by Cancer Patients who Live in Minority Versus White Areas. <i>Journal of General Internal Medicine</i> , 2007, 22, 396-399.	1.3	58
237	Predictors of Diagnosis Delay and Complications for Newly-Diagnosed Myeloma Patients.. <i>Blood</i> , 2007, 110, 368-368.	0.6	2
238	Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1108-1117.	3.0	299
239	Efficacy of Cetuximab After Treatment with Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Based Chemotherapy in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2006, 6, 59-65.	1.0	10
240	Phase I Study of Gefitinib plus FOLFIRI in Previously Untreated Patients with Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2006, 6, 208-213.	1.0	21
241	The Combination of Capecitabine and Thalidomide in Previously Treated, Refractory Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 40-44.	0.6	13
242	A Phase II Trial of Irinotecan and Cisplatin in Patients with Metastatic Neuroendocrine Tumors. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1033-1038.	1.1	82
243	Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 285-293.	1.1	29
244	Associations Between Hospital and Surgeon Procedure Volumes and Patient Outcomes After Ovarian Cancer Resection. <i>Journal of the National Cancer Institute</i> , 2006, 98, 163-171.	3.0	157
245	Measuring Disease-Free Survival and Cancer Relapse Using Medicare Claims From CALGB Breast Cancer Trial Participants (Companion to 9344). <i>Journal of the National Cancer Institute</i> , 2006, 98, 1335-1338.	3.0	73
246	The Effect of Race on Invasive Staging and Surgery in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 413-418.	0.8	216
247	Surgical Mortality in Patients With Esophageal Cancer: Development and Validation of a Simple Risk Score. <i>Journal of Clinical Oncology</i> , 2006, 24, 4277-4284.	0.8	219
248	Radiation Therapy After Mastectomy Between 1991 and 1999 in Elderly Women: Response to Clinical Trial Information. <i>Journal of Clinical Oncology</i> , 2006, 24, 3474-3482.	0.8	23
249	Phase II Study of Capecitabine, Oxaliplatin, and Erlotinib in Previously Treated Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 1892-1897.	0.8	94
250	Effect of Surgeon Specialty on Processes of Care and Outcomes for Ovarian Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2006, 98, 172-180.	3.0	363
251	Failing to Plan Is Planning to Fail: Improving the Quality of Care With Survivorship Care Plans. <i>Journal of Clinical Oncology</i> , 2006, 24, 5112-5116.	0.8	256
252	Towards using administrative databases to measure population-based indicators of quality of end-of-life care: testing the methodology. <i>Palliative Medicine</i> , 2006, 20, 769-777.	1.3	130

#	ARTICLE	IF	CITATIONS
253	<p>Handbook of Palliative Oral Care in Advanced Disease; Supportive Care for the Renal Patient; Handbook of Opioid Bowel Syndrome Oral Care in Advanced Disease. Edited by Andrew Davies and Ilora Finley . New York: Oxford University Press, 2005, 221 pp., \$75.00</p> <p>Supportive Care for the Renal Patient. Edited by E. Joanna Chambers , Michael Germain , and Edwina Brown . New York: Oxford University Press, 2004, 276 pp., \$95.00 (hardcover)</p> <p>Handbook of Opioid Bowel Syndrome. Edited by Chun-Su Yuan , M.D., Ph.D. Bin. <i>Journal of Palliative Medicine</i>, 2006, 9, 814-817.</p>	0.6	0
254	Looking Back From Death: The Value of Retrospective Studies of End-of-Life Care. <i>Journal of Clinical Oncology</i> , 2006, 24, 838-840.	0.8	113
255	A Phase II Trial of Irinotecan in Patients with Previously Untreated Advanced Esophageal and Gastric Adenocarcinoma. <i>Digestive Diseases and Sciences</i> , 2005, 50, 2218-2223.	1.1	51
256	Evaluating claims-based indicators of the intensity of end-of-life cancer care. <i>International Journal for Quality in Health Care</i> , 2005, 17, 505-509.	0.9	326
257	Trends in the Treatment of Acute Myeloid Leukaemia in the Elderly. <i>Drugs and Aging</i> , 2005, 22, 943-955.	1.3	79
258	Trends in the Aggressiveness of Cancer Care Near the End of Life. <i>Journal of Clinical Oncology</i> , 2004, 22, 315-321.	0.8	858
259	Under use of necessary care among cancer survivors. <i>Cancer</i> , 2004, 101, 1712-1719.	2.0	433
260	Two schedules of second-line irinotecan for metastatic colon carcinoma. <i>Cancer</i> , 2004, 101, 2533-2539.	2.0	9
261	Treatment Patterns, Outcomes and Costs Among Elderly Patients with Chronic Myeloid Leukaemia. <i>Drugs and Aging</i> , 2004, 21, 737-746.	1.3	15
262	Treatment of Locally Advanced Pancreatic Cancer in the Real World: Population-Based Practices and Effectiveness. <i>Journal of Clinical Oncology</i> , 2003, 21, 3409-3414.	0.8	93
263	Patterns of Care Studies: Creating "An Environment of Watchful Concern" <i>Journal of Clinical Oncology</i> , 2003, 21, 4479-4480.	0.8	14
264	Quality of Non-Breast Cancer Health Maintenance Among Elderly Breast Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2003, 21, 1447-1451.	0.8	273
265	A Phase II Study of Modified deGramont 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Treated Patients with Metastatic Colorectal Cancer. <i>Cancer Investigation</i> , 2003, 21, 505-511.	0.6	6
266	Influenza Vaccination in Elderly Patients With Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 1161-1166.	0.8	61
267	Identifying Potential Indicators of the Quality of End-of-Life Cancer Care From Administrative Data. <i>Journal of Clinical Oncology</i> , 2003, 21, 1133-1138.	0.8	722
268	Prognostic Factors Following Curative Resection for Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2003, 237, 74-85.	2.1	518
269	Impact of Referral Patterns on the Use of Chemotherapy for Lung Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 1786-1792.	0.8	163
270	Identifying Cancer Relapse Using SEER-Medicare Data. <i>Medical Care</i> , 2002, 40, IV-75-IV-81.	1.1	93

#	ARTICLE	IF	CITATIONS
271	An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. <i>Annals of Thoracic Surgery</i> , 2002, 74, 1026-1032.	0.7	196
272	Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia. <i>American Journal of Health-System Pharmacy</i> , 2002, 59, 941-948.	0.5	7
273	A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. <i>Cancer</i> , 2002, 94, 97-103.	2.0	89
274	A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2002, 94, 3186-3191.	2.0	95
275	Neoadjuvant or adjuvant therapy for resectable gastric cancer? A practice guideline. <i>Canadian Journal of Surgery</i> , 2002, 45, 438-46.	0.5	18
276	Effectiveness of Chemotherapy for Advanced Lung Cancer in the Elderly: Instrumental Variable and Propensity Analysis. <i>Journal of Clinical Oncology</i> , 2001, 19, 1064-1070.	0.8	226
277	Thymidylate Synthase Expression in Stage II and III Colon Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001, 24, 597-602.	0.6	30
278	Who Gets Chemotherapy for Metastatic Lung Cancer?. <i>Chest</i> , 2000, 117, 1239-1246.	0.4	216
279	An Assessment of Methods to Combine Published Survival Curves. <i>Medical Decision Making</i> , 2000, 20, 104-111.	1.2	53
280	Decision Framework for Chemotherapeutic Interventions for Metastatic Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1321-1329.	3.0	62
281	Outcomes Research in Oncology: History, Conceptual Framework, and Trends in the Literature. <i>Journal of the National Cancer Institute</i> , 2000, 92, 195-204.	3.0	79
282	The cost of radiotherapy at an Ontario regional cancer centre: a re-evaluation. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 32, 87-93.	2.0	25
283	Management Issues for Stage IV Non-Small-Cell Lung Cancer. <i>Cancer Control</i> , 1997, 4, 307-316.	0.7	15